RENEURON GRP (RENE.L, LSE, LSE:RENE)

RENE Share PerformanceMore

52 week high4.1900 07/11/13
52 week low2.7100 23/12/13
52 week change -0.4000 (-10.26%)
4 week volume38,883,819 28/08/14

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Directors' Interest in Shares and Share Options

Notification of issuers, persons discharging managerial responsibilities and their connected persons in respect of transactions conducted in their own account in shares of the issuer

Block Listing Six Monthly Review

Six monthly notification by a company issuing securities on aregular basisNotification of a company’s annual report & accounts

New CEO appointed at ReNeuron Group

ReNeuron Group (AIM: RENE), a UK-based stem cell therapy company, has announced that Olav Helleb, is to become its ...

Appointment of CEO

Miscellaneous medium priority announcements

Notification of Major Interest in Shares

Notification of major interests in shares

Result of 2014 Annual General Meeting

Notification of the result of any voting at an AGM

ReNeuron start two new clinical trials

ReNeuron Group (AIM: RENE), a leading UK-based stem cell therapy company, has reported that its core therapeutic pro...

AGM Trading Update

Miscellaneous medium priority announcements

Fundamental DataMore

EPS-0.5
Dividend yield0 %

Equity Research (RENE)

edison investment research
ReNeuron Group plc
08/05/2014
Long-term data from the PISCES Phase I study of ReNeuron’s neural stem cell product ReN001 in 11 disabled stroke patients provide further evidence of safety and encouraging signals of efficacy. The...

Users' HoldingsMore

Users who hold RENEURON GRP also hold..
BARCLAYS13%
ROYAL BANK OF SCOTLAND GROUP12%
LLOYDS BANKING GROUP11%
BP11%
FALKLAND OIL & GAS10%